Correlation between 18F-FDG-uptake and in vitro chemosensitivity of cisplatin in head and neck cancer.
High [18F]-2-fluorodeoxyglucose (18F-FDG) -uptake of primary tumor, assessed by pretreatment positron emission tomography combined computed tomography (PET/CT), has indicated poor overall survival (OS) in head and neck cancer (HNC).We investigated the correlation between 18F-FDG-uptake and in vitro chemosensitivity of cisplatin using histoculture drug response assay in HNC. Twenty-eight patients were evaluated. The maximum standardized uptake value (SUVmax) and inhibition index (I.I.) cisplatin were calculated as 18F-FDG-uptake and in vitro chemosensitivity of cisplatin. Each SUVmax10.5 or I.I.cisplatin<50 could significantly differentiate shorter survival group by OS analyses. I.I.cisplatin of patients with SUVmax≥10.5 was significantly greater. In 19 patients with SUVmax≥10.5, those who received treatment with cisplatin-based chemotherapy exhibited a significant correlation with longer OS. Cisplatin hasthe potential to improve OS for HNC patients that were predicted as shorter OS by 18F-FDG-PET/CT.